Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Alicia Levey and Kiren Khanduja of Pionyr Immunotherapeutics — a San Francisco-based biotech with a pipeline of first-in-class clinical-stage cancer immunotherapies targeting the tumor microenvironment — discuss the basis for selection of Lonza to meet Pionyr’s goals to rapidly develop a third lead candidate from the start and to scale-up manufacturing of two clinical-stage immuno-oncology treatments after tech transfer.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.